During Monday’s current trade, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s shares incline 0.24% to $4.12.
Arena Pharmaceuticals, Inc. (ARNA) declared that Steve Chalgren , Arena’s executive vice president of product administration and chief strategy officer, will speak at the CIMdata PLM Road Map conference for the High Tech Electronics Community, taking place June 16, 2015 at the Biltmore Hotel & Suites in Santa Clara, California .
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults. It is also developing a portfolio of programs in various therapeutic areas, counting cardiovascular, central nervous system, and metabolic diseases. Its products under development comprise Ralinepag, an agonist of the prostacyclin receptor intended for the treatment of vascular diseases, counting potentially pulmonary arterial hypertension that is in Phase II clinical trials.
Norfolk Southern Corp. (NYSE:NSC)‘s shares drop -0.26% to $91.46, during the current trading session Monday’s, hitting its highest level.
Norfolk Southern Corp. (NSC) stated first-quarter 2015 earnings of $1.00 per share, down 14.5% year over year but in line with the Zacks Consensus Estimate. Total operating revenue of $2,567 million was down 4.5% year over year and also below our estimate of $2,667 million.
Investors’ apprehension about the company’s forthcoming earnings release raised after MO-based Kansas City Southern KSU withdrew its 2015 revenue and volume outlook at the Bank of America Merrill Lynch 2015 transportation conference. Apprehensions were fueled when another railroad operator Union Pacific Corp. UNP painted a dismal picture with respect to coal shipments at the Wolfe research 8th annual global transportation conference.
Norfolk Southern Corporation, together with its auxiliaries, engages in the rail transportation of raw materials, intermediate products, and finished goods. As of December 31, 2014, it operated about 20,000 miles of road in 22 states and the District of Columbia. The company also operates planned passenger trains; transports overseas freight through various Atlantic and Gulf Coast ports; and provides logistics services.
In a afternoon trade, CorMedix Inc. (NYSEMKT:CRMD)‘s shares plunge -8.94% to $4.48.
CorMedix Inc. (CRMD) a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, recently declared a presentation on Neutrolin® post marketing surveillance data at the 52nd European Dialysis and Transplant Association (ERA-EDTA) Congress. The Neutrolin Usage Monitoring Program is a post-approval surveillance program monitoring the routine use of Neutrolin, a novel catheter lock solution, in hemodialysis patients with tunneled central venous catheters (CVC). The program measures the number of catheter related blood stream infections (CRBSI), and the number of pre-mature CVC removals due to infection and/ or thrombosis. The secondary outcome measure was biofilm formation in CVCs. Other outcome measures comprised of economic effects derived from using Neutrolin and effectiveness in the high risk groups (e.g. diabetic patients).
The poster, titled Neutrolin, A Catheter Lock Solution (CLS) with No Stated Human Resistance, Significantly Reduces the Rates of Infection and Thrombosis in Hemodialysis Patients Enrolled in a Post-Approval Surveillance Study, was presented on May 30, 2015. In 120 patients, the results to-date comprise three infections and two thromboses in 21,151 hemodialysis catheter-days. The Neutrolin Usage Monitoring Program results can be calculated as 0.14 infections per 1,000 catheter days (as compared to benchmark of 3.5 per 1,000 catheter days), a 96% reduction in infection rate, and 0.09 thrombosis per 1,000 catheter days (as compared to benchmark 2-3 per 1,000 catheter days), a 96% reduction in the rate of thrombosis.
CorMedix Inc., a pharmaceutical company, intends to in-license, develop, and commercialize therapeutic products for the prevention and treatment of cardiac, renal, and infectious diseases.
RR Donnelley & Sons Co (NASDAQ:RRD), during its Monday’s current trading session -2.12% loss and closed at $18.20.
RR Donnelley & Sons Co (RRD) declared that it has accomplished its formerly declared acquisition of Courier Corporation, one of America’s major book manufacturers in addition to a leader in content administration and customization in new and traditional media.
R.R. Donnelley & Sons Company provides integrated communications solutions to private and public sector clients in the United States and internationally. The company operates through Publishing and Retail Services, Variable Print, Planned Services, and International segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.